Can Fatty Liver Cause an Enlarged Spleen?

Fatty liver disease and an enlarged spleen are more closely linked than many people realise. Fatty liver can cause an enlarged spleen, but this connection typically emerges only when the disease has advanced to cirrhosis and portal hypertension. In early stages, fatty liver rarely affects the spleen directly. Understanding how progressive liver scarring disrupts blood flow, what symptoms to watch for, and when to seek medical advice is essential for anyone living with fatty liver disease or concerned about its long-term complications.

Can fatty liver really cause your spleen to become enlarged?

Fatty liver can cause spleen enlargement, but only when it has progressed to cirrhosis and portal hypertension, which obstructs portal blood flow and causes the spleen to become congested. Early-stage fatty liver does not directly affect the spleen.

Fatty liver disease can cause an enlarged spleen, but this typically occurs only when the condition has progressed to advanced fibrosis or cirrhosis with portal hypertension. In its early stages, fatty liver (medically termed hepatic steatosis) does not directly affect the spleen. However, when fat accumulation leads to persistent inflammation, progressive scarring, and eventually cirrhosis, the resulting changes in blood flow through the liver can cause the spleen to enlarge, a condition called splenomegaly.

The mechanism behind this involves a complication called portal hypertension. Cirrhosis causes the liver to become stiff and scarred, which obstructs the normal flow of blood through the portal vein, the large vessel that carries blood from the digestive organs to the liver. This obstruction raises pressure within the portal venous system. The spleen, which drains blood into the portal vein, responds to this increased pressure by becoming congested and enlarged.

It is worth noting that splenomegaly has many possible causes beyond liver disease, including certain blood disorders, infections, and other conditions. An enlarged spleen always warrants proper assessment by a GP or specialist to identify the underlying cause.

Not everyone with fatty liver disease will develop cirrhosis. Non-alcoholic fatty liver disease (NAFLD), now increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), progresses to cirrhosis in a minority of cases, particularly in those with additional risk factors such as obesity, type 2 diabetes, or heavy alcohol use.^[5][6] Many UK resources, including NICE and the NHS, continue to use both terms, so you may encounter either. Alcoholic liver disease carries a higher risk of progression when alcohol consumption continues.

If you have been diagnosed with fatty liver disease and are concerned about progression, speaking to your GP is the appropriate first step. Early lifestyle intervention can significantly slow or even reverse early-stage fatty liver before complications such as portal hypertension and splenomegaly develop.

What symptoms should you look out for with an enlarged spleen?

An enlarged spleen often causes no symptoms initially, but may produce a dull ache or fullness in the upper left abdomen, fatigue, easy bruising, or breathlessness due to hypersplenism. Sudden severe left-sided abdominal pain may indicate splenic rupture, requiring immediate emergency care.

An enlarged spleen often causes no symptoms at all in its early stages, which is why it is frequently discovered incidentally during imaging carried out for another reason. When symptoms do occur, the most common is a dull, persistent ache or a feeling of fullness in the upper left side of the abdomen, sometimes extending to the left shoulder. This discomfort may worsen after eating, as the enlarged spleen presses against the stomach.

Because the spleen plays a central role in filtering blood and supporting immune function, splenomegaly can lead to a condition called hypersplenism, where the spleen becomes overactive and removes blood cells too rapidly. This can result in:

• Anaemia (low red blood cell count), causing fatigue, pallor and breathlessness

• Thrombocytopenia (low platelet count), increasing the risk of bruising and bleeding

• Leucopenia (low white blood cell count), making infections more likely

In the context of advanced liver disease and portal hypertension, additional symptoms may be present that reflect the underlying condition rather than the spleen itself. These include jaundice (yellowing of the skin or whites of the eyes), abdominal swelling due to fluid accumulation (ascites), and visible dilated veins on the abdomen.

Portal hypertension can also cause fragile, enlarged veins (varices) to develop in the oesophagus or stomach. If these rupture, they can cause vomiting of blood or passing of black, tarry stools (melaena). These are medical emergencies: call 999 or go immediately to your nearest accident and emergency department if either occurs.

If you have a confirmed enlarged spleen, you should avoid contact sports and activities that risk a blow to the abdomen until your doctor advises it is safe to do so. An enlarged spleen is more vulnerable to rupture from trauma than a normal-sized spleen.

Contact your GP promptly if you notice unexplained left-sided abdominal pain, persistent fatigue, easy bruising, or yellowing of the skin. If you experience sudden, severe pain in the upper left abdomen, this may indicate a ruptured spleen, which is a medical emergency requiring immediate attendance at an accident and emergency department or a call to 999.

How is an enlarged spleen diagnosed alongside liver disease?

Abdominal ultrasound is the first-line investigation, assessing both liver and spleen size and portal blood flow; a spleen exceeding 12 centimetres is a common threshold for enlargement. Blood tests, FibroScan, and endoscopy may follow depending on clinical findings.

An enlarged spleen is most commonly identified through abdominal imaging, with ultrasound being the first-line investigation recommended in UK clinical practice. Ultrasound is non-invasive, widely available on the NHS, and can assess both the liver and spleen simultaneously, providing information about organ size, texture, and blood flow through the portal vein using Doppler techniques. A spleen measuring more than 12 centimetres in its longest dimension on ultrasound is often used as a guide for enlargement in adults, though normal ranges vary with sex and body habitus, and clinical context always guides interpretation.

Where ultrasound findings are inconclusive or where more detailed assessment is needed, a CT (computed tomography) scan or MRI (magnetic resonance imaging) may be arranged. These provide greater anatomical detail and can help identify features of portal hypertension such as collateral vessels or ascites, though they are not the standard test for diagnosing or grading varices.

Oesophageal and gastric varices are primarily diagnosed and risk-stratified by upper gastrointestinal endoscopy, which allows direct visualisation and, where appropriate, treatment at the same time. NICE guidance (NG50) recommends endoscopic surveillance for people with confirmed cirrhosis.^[2][3]

Blood tests form an essential part of the diagnostic workup. A full blood count may reveal the cytopenias associated with hypersplenism, while liver function tests, clotting studies, and markers such as albumin and bilirubin help assess the degree of liver impairment. Non-invasive liver fibrosis assessments, including the FIB-4 score and transient elastography (FibroScan), are used in line with NICE guidance (NG49) to estimate the degree of liver scarring without the need for a biopsy.^[5][6] Your GP or specialist team can advise on which assessments are appropriate for your situation and what the results mean.

Your GP or gastroenterology team will coordinate these investigations based on your individual clinical picture and local NHS pathways.

What treatment options are available on the NHS?

NHS treatment focuses on the underlying liver disease, with NICE-recommended lifestyle changes as the cornerstone for fatty liver. Portal hypertension complications are managed with beta-blockers, endoscopic band ligation, diuretics, or TIPS, with liver transplantation considered in end-stage disease.

Treatment for an enlarged spleen caused by liver disease focuses primarily on managing the underlying liver condition and its complications, rather than treating the spleen in isolation. For fatty liver disease, NICE guidance (NG49) emphasises lifestyle modification as the cornerstone of management. This includes achieving and maintaining a healthy weight, following a balanced diet, increasing physical activity, and abstaining from alcohol. Evidence cited in NICE guidance indicates that even a modest reduction in body weight of 5 to 10 per cent can reduce liver fat and inflammation in people with NAFLD or MASLD.^[5][6]

Where portal hypertension is present, management is guided by specialist assessment and may include:

• Beta-blockers (such as propranolol or carvedilol) to reduce portal pressure and lower the risk of variceal bleeding, initiated under specialist supervision following endoscopic assessment or haemodynamic evaluation^[4][9]

• Endoscopic band ligation to treat oesophageal varices identified on endoscopy

• Diuretics (such as spironolactone and furosemide) to manage ascites, alongside dietary sodium restriction; large-volume paracentesis with albumin replacement is a standard option for tense or refractory ascites in UK practice^[3][2]

• Transjugular intrahepatic portosystemic shunt (TIPS), a specialist procedure to relieve portal hypertension in selected patients

In cases of end-stage liver disease, liver transplantation may be considered for eligible patients through specialist hepatology centres. Successful transplantation typically resolves portal hypertension and allows the spleen to return towards a normal size over time.^[14][15]

For people with type 2 diabetes or obesity contributing to liver disease, medication review is important. Some medicines used in metabolic conditions may have beneficial effects on liver health, and your GP or specialist team can advise on the most appropriate options for your circumstances.

NHS referral to a hepatologist or gastroenterologist is appropriate for anyone with confirmed cirrhosis, significant fibrosis, or complications such as splenomegaly, ascites, or variceal bleeding. Speak to your GP to discuss referral and to ensure you are receiving the right level of monitoring and support.

Scientific References

1. Spleen problems and spleen removal.
2. Cirrhosis in over 16s: assessment and management (NG50).
3. Cirrhosis in over 16s: assessment and management (NG50) – Recommendations chapter.
4. NG50 – Clinical and cost-effectiveness of non-selective beta-blockers and endoscopic variceal band ligation for primary prevention of bleeding in people with oesophageal varices due to cirrhosis.
5. Metabolic dysfunction-associated steatotic liver disease (MASLD) / Non-alcoholic fatty liver disease (NAFLD) (NG49).
6. Non-alcoholic fatty liver disease (NAFLD) – Short version of draft guideline (NG49).
7. Non-alcoholic fatty liver disease (NAFLD).
8. The Role of the Spleen in Portal Hypertension.
9. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
10. NSBBs, EBL or Combined Therapy for High-Risk Varices: Systematic Review and Meta-Analysis. Liver International.
11. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database of Systematic Reviews.
12. Existing assessments of this procedure – albumin replacement in large-volume paracentesis.
13. Use of Intravenous Albumin: A Guideline From the International Collaboration for Transfusion Medicine Guidelines. Chest.
14. Spleen stiffness can non-invasively assess resolution of portal hypertension after liver transplantation.
15. Course of Portal Hypertension and Its Prognostic Impact After Liver Transplantation. United European Gastroenterology Journal.
16. Genetic and non-genetic drivers of histological progression in MASLD. Nature Communications.
17. Non-cirrhotic portal hypertension – diagnosis and management. Journal of Hepatology.

Frequently Asked Questions